Log In Sign up
The largest database of trusted experimental protocols

Anti eif4e

Manufactured by Abcam
Visit Supplier
Sourced in China

Anti-eIF4E is a primary antibody that specifically binds to the eIF4E (eukaryotic translation initiation factor 4E) protein. eIF4E is a key component of the eukaryotic translation initiation complex and plays a critical role in the regulation of protein synthesis. This antibody can be used for the detection and quantification of eIF4E in various experimental applications.

Automatically generated - may contain errors

Lab products found in correlation

Ecl western blotting protocol, by GE Healthcare (1 mentions) Anti lkb1, by Immunoway (1 mentions) Anti hnrnpd, by Thermo Fisher Scientific (1 mentions) Anti ago2, by Merck Group (1 mentions) Anti mff, by Proteintech (1 mentions) Anti vegfa, by Proteintech (1 mentions) Pvdf membrane, by Merck Group (1 mentions) Bcl xl, by Abcam (1 mentions) Bcl 2, by Santa Cruz Biotechnology (1 mentions) Gapdh, by Beyotime (1 mentions) Anti β actin, by Santa Cruz Biotechnology (1 mentions)

Close spelling variants of this product

EIF4E (10 citations) Anti-eIF4E antibody (2 citations)

3 protocols using anti eif4e

1

Comprehensive Western Blot Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
For western blots, samples were separated on SDS‐PAGE gels and then transferred to PVDF membranes (Millipore). Membranes were processed according to the ECL western blotting protocol (GE Healthcare). The grayscale statistics of western blotting were performed by ImageJ. The following antibodies were used in western blots: anti‐AMPK (CST, 5832), anti‐p‐AMPK (CST, 2535), anti‐ACC1 (CST, 3676), anti‐p‐ACC1 (CST, 3661), anti‐RAPTOR (CST, 2280), anti‐p‐RAPTOR (CST, 89146), anti‐VEGFA (Proteintech, 9003‐1‐AP), anti‐TGF‐β (Immunoway, YT4632), anti‐MFF (Proteintech, 17090‐1‐AP), anti‐p‐MFF (Immunoway, YP1403), anti‐p‐ULK1 (CST, 5869), anti‐ULK1 (CST, 8054), anti‐LKB1 (Immunoway, YT2573), anti‐HNRNPD (Thermo, PA5‐99469), anti‐AGO2 (Sigma, SAB4200085), anti‐eIF4G1 (CST, 8701), anti‐eIF4E (Abcam, ab33768), anti‐c‐MYC (CST, 9402), and anti‐ACTB (TransGen, HC201). Antibody validation is provided on the manufacturers’ websites.
Li J., Wang X., Shi L., Liu B., Sheng Z., Chang S., Cai X, & Shan G. (2023). A Mammalian Conserved Circular RNA CircLARP1B Regulates Hepatocellular Carcinoma Metastasis and Lipid Metabolism. Advanced Science, 11(2), 2305902.
+ Open protocol
+ Expand
2

Immunoblotting of Apoptosis Regulators

Check if the same lab product or an alternative is used in the 5 most similar protocols
Immunoblotting was conducted as previously described.22 (link) The primary antibodies used in this study were as follows: anti-poly (ADP-ribose) polymerase 1 (PARP, Abcam, Cambridge, MA, USA), anti-BCL2 apoptosis regulator (Bcl-2, Santa Cruz, Dallas, TX, USA), anti-MCL1 apoptosis regulator (Mcl-1, Cell Signaling Technology, Danvers, MA, USA), anti-BCL2 like 1 (Bcl-xL, Abcam), anti-BCL2 associated X (BAX, Abcam), anti-BCL2 antagonist/killer 1 (BAK, Abcam), anti-phosphorylated AKT serine/threonine kinase 1 (p-AKT, Cell Signaling Technology), anti-phosphorylated mitogen-activated protein kinase 1 (p-ERK, Cell Signaling Technology), anti-phosphorylated mechanistic target of rapamycin kinase (p-mTOR, Cell Signaling Technology), anti-MYC proto-oncogene (c-Myc, Abcam), anti-EIF4E (Abcam) and anti- glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Beyotime, Shanghai, China).
Guo C., Gong M, & Li Z. (2020). Knockdown of lncRNA MCM3AP-AS1 Attenuates Chemoresistance of Burkitt Lymphoma to Doxorubicin Treatment via Targeting the miR-15a/EIF4E Axis. Cancer Management and Research, 12, 5845-5855.
+ Open protocol
+ Expand
3

Evaluating eIF4E Expression in Breast Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
MDA-MB-231 and MDA-MB-231.DR cells were seeded into 6-well plates (1.5 × 105 cells/well) and allowed to adhere overnight. The cells were then treated with RGD-PEG(HZ)-ECO/siRNA complexes (N/P=8, siRNA concentration of 100 nM) in complete growth medium. After 5 days, detergent-solubilized whole cell extracts were prepared by lysing the cells in Buffer H (50 mM β-glycerophosphate, 1.5 mM EGTA, 1 mM DTT, 0.2 mM sodium orthovanadate, 1 mM benzamidine, 10 mg/mL leupeptin, and 10 mg/mL aprotinin, pH 7.3). The clarified extracts (20 mg/lane) were separated through 10% SDS-PAGE, transferred electrophoretically to nitrocellulose membranes, and immunoblotted with the primary antibodies, anti-eIF4E (1:1000; Abcam, Cambridge, MA) and anti-β-actin (1:1000; Santa Cruz Biotechnology, Dallas, Texas).
Gujrati M., Mack M., Snyder D., Vaidya A.M., Malamas A, & Lu Z.R. (2016). Targeted dual pH-sensitive lipid siRNA self-assembly nanoparticles facilitate in vivo cytosolic siRNA delivery in tumor and overcome drug resistance by silencing eIF4E in breast cancer therapy. Advanced healthcare materials, 5(22), 2882-2895.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!